ADTX) announces the publication of an innovative mathematical model
Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.
Aditxt (NASDAQ: ADTX), a biotechnology innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the publication of a mathematical model to predict the durability and decay rate of neutralizing antibodies against SARS. -CoV-2 in a peer-reviewed research article in the Journal of Theoretical Biology. The publication, entitled “A mathematical model of the intra-host kinetics of SARS-CoV-2 neutralizing antibodies after vaccination against COVID-19”, describes a model developed with Dr. Lisette de Pillis, professor of life sciences and mathematics at Harvey Mudd College. NAbs inhibit viral binding to the human cell receptor, thereby reducing the ability to infect the cell. The researchers say assessing NAb levels and their durability over time is important for understanding unique immune responses and the likelihood that an individual has protective immunity against infection. The AditxtScore(TM) model uses a new immune monitoring tool based on flow cytometry to determine NAb levels after immunization.
To view the full press release, visit https://ibn.fm/i3lQl
About Aditxt Inc.
Aditxt is a biotechnology innovation company that develops and commercializes technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to transplant organ rejection, autoimmune diseases and allergies. For more information, please visit www.aditxt.com and www.AditxtScore.com.
NOTICE TO INVESTORS: The latest ADTX news and updates are available from the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communications solutions. As a multi-faceted financial news and content distribution company with an extensive team of journalists and writers, BMW is uniquely positioned to best serve private and public companies wishing to reach large audiences. investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 major syndication outlets across the country. By reducing the information overload in today’s market, BMW provides customers with unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS alerts from BioMedWire, text “Biotech” to 844-397-5787 (US cell phones only)
For more information, please visit https://www.BioMedWire.com
Please review the full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever posted or republished: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
